Pharmaceutical company Galderma has announced that China’s National Medical Products Administration (NPA) has approved Relfydess (relabotulinumtoxinA) for the temporary improvement of moderate-to-severe glabellar lines in adults. The approval is supported
Aesthetic pharmaceutical company Galderma hosted an event at The Gherkin for the UK launch of its new neuromodulator, Relfydess, on June 3. The event featured expert insights from Dr Javier
Aesthetic pharmaceutical company Galderma will release its liquid neuromodulator RelabotulinumtoxinA (Relfydess) in the UK this month. Galderma explains Relfydess is designed to deliver fast and sustained results for glabellar and
